Biogen strikes $1 billion deal with Denali to advance Parkinson’s drug based on approach that was nearly abandoned (STAT Plus)

More reads:

• Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda? (Fierce Pharma)
• Covid opens new doors for China's gene giant (Reuters)
• Pandemic lays bare U.S. reliance on China for drugs (Wall Street Journal)
• White House seeks crackdown on U.S.-listed Chinese firms (Wall Street Journal)
• Biogen strikes $1 billion deal with Denali to advance Parkinson’s drug based on approach that was nearly abandoned (STAT Plus)